PolyPid (NASDAQ:PYPD) Announces Quarterly Earnings Results

PolyPid (NASDAQ:PYPD) issued its quarterly earnings results on Wednesday. The company reported ($1.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.23), Zacks reports.

PolyPid Trading Up 0.7 %

Shares of NASDAQ:PYPD traded up $0.02 during mid-day trading on Wednesday, hitting $2.91. The stock had a trading volume of 5,177 shares, compared to its average volume of 22,431. The company’s 50 day moving average is $3.02 and its 200-day moving average is $3.32. PolyPid has a 12-month low of $2.37 and a 12-month high of $7.00. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.00. The company has a market cap of $29.64 million, a PE ratio of -0.37 and a beta of 1.32.

Analysts Set New Price Targets

Several analysts recently commented on PYPD shares. Craig Hallum began coverage on shares of PolyPid in a research note on Monday, November 4th. They set a “buy” rating and a $10.00 target price for the company. HC Wainwright cut their price objective on PolyPid from $14.00 to $11.00 and set a “buy” rating for the company in a research report on Thursday, December 26th. Rodman & Renshaw initiated coverage on PolyPid in a report on Tuesday, January 28th. They issued a “buy” rating and a $13.00 target price on the stock. Finally, RODMAN&RENSHAW raised PolyPid to a “strong-buy” rating in a report on Tuesday, January 28th.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.